Tin tức & Cập nhật
Xem bài viết Gan
Xem

Patient ethnicity, HBV genotype predict functional cure after therapy withdrawal
The chances of hepatitis B surface antigen (HBsAg) loss after withdrawing nucleo(s)tide analogue (NUC) treatment depend on factors such as patient ethnicity, end-of-treatment antigen levels, and HBV genotype, a new study reports.

Fenofibrate keeps lid on triglyceride in NASH patients receiving ACC inhibitor
For nonalcoholic steatohepatitis (NASH) patients with hypertriglyceridaemia, treatment with fenofibrate helps reduce the increases in triglyceride levels associated with acetyl-coenzyme A carboxylase (ACC) inhibition, as shown in a study.

First-line cabozantinib-atezolizumab boosts PFS in advanced HCC
The combination of cabozantinib and atezolizumab in the first-line setting significantly improved progression-free survival (PFS) compared with sorafenib in patients with advanced hepatocellular carcinoma (HCC), according to results of the phase III COSMIC-312 trial presented at ESMO Asia 2021.





